MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » pSivida-Alimera eye treatment still a no-go for the FDA

pSivida-Alimera eye treatment still a no-go for the FDA

By

The FDA rejected pSivida Corp.’s (NSDQ:PSDV) and Alimera Sciences Inc.’s (NSDQ:ALIM)  resubmitted new drug application for the Iluvien eye treatment, citing a lack of safety and efficacy data.

Iluvien is designed to deliver sustained, low doses of flucocinolone acetonide to the retina at the rear of the eyeball in patients with diabetic macular edema.

The federal watchdog agency said the risk of reaction shown in the companies’ clinical study were significant and that the NDA did not provide sufficient data to prove that the drug’s benefits outweighed its risks.

Sign up to get our free newsletters delivered straight to your inbox

The FDA called for two additional clinical trials to demonstrate Iluvien’s safety and efficacy in treating diabetic macular edema.

"We are obviously surprised and disappointed with the FDA’s decision," Paul Ashton, president & CEO of pSivida said in prepared remarks.

Watertown, Mass.-based pSivida’s partner Alimera resubmitted a new drug application to the federal watchdog agency in May, 11 months after the companies’ first NDA.

The companies received a rejection letter from the FDA for the drug-device combination last December.

The FDA requested additional analysis of safety and efficacy data from the companies’ FAME study along with additional information on specifications on the manufacturing, packaging and sterilization of the drug by third-party manufacturers, according to the companies.

"We believe the additional data we recently released will help the FDA further evaluate the safety and efficacy of Iluvien," said Alimera CEO Dan Myers when the NDA was resubmitted." In addition, the third-party manufacturing deficiencies identified in the CRL have been resolved."

Upon approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits of the drug, the company said.

pSivida will hold a press conference to discuss the FDA’s decision on Monday, Nov. 14 at 9:00am.

In case you missed it

RSS From Medical Design & Outsourcing

  • Respira Labs seeks FDA clearance for its wearable lung monitor
    Respira Labs recently announced that it has developed a wearable device that continuously assesses lung function without the need for traditional pulmonary function tests. Mountain View, California-based Respira Labs designed its Sylvee wearable initially to assess chronic obstructive pulmonary disease, COVID-19 and asthma patients. It is embedded with speakers and microphones that measure the change… […]
  • Owen Mumford starts work on new production center in U.K.
    Owen Mumford this week announced that it has started building its new production facility in Witney, Oxfordshire in the U.K. Owen Mumford’s new Witney facility will stand as a production site for the company’s recently launched, next-generation auto-injector Aidaptus. The company has decades of experience creating its own drug delivery, blood sampling and rapid diagnostic… […]
  • FDA’s Woodcock reassures about COVID-19 tests, vaccines under Omicron
    Acting FDA Commissioner Dr. Janet Woodcock thinks many COVID-19 tests will continue to work with the new Omicron variant — with information coming soon on vaccine efficacy. In a statement posted yesterday, Woodcock said she thought the agency is well-positioned to work with companies to address the potential impact of viral mutations on COVID-19 tests,… […]
  • Traco Power launches THM 60WI DC-DC converters
    Traco Power today announced it has launched its THM 60WI series of quarter brick DC-DC converters. The Baar, Switzerlad-based company designed the DC-DC converters with ultra-wide input ranges and safety approvals for medical and industrial applications. Traco Power’s THM 60WI series of converters consists of 12 models with 9-75 or 18-75 Vin ranges with single… […]
  • The 10 largest medtech employers of 2021 – and what their employees really think
    Employees of the 10 largest medtech employers are proud of working on life-saving products — with a greater appreciation for diversity and inclusion initiatives. That was one major takeaway as Medical Design & Outsourcing compiled some current and former employee reviews posted on Glassdoor. (Browse the online version of our Big 100 report.) Despite the pride, there was… […]
  • COVID-19 test makers say their products also detect Omicron
    Abbott, BD, Hologic, PerkinElmer, Thermo Fisher and Quidel are reassuring the public that their COVID-19 tests detect the Omicron variant. Discovered last week in South Africa, the new variant has enough mutations that it has raised concerns worldwide — even though it is still unknown for sure whether the mutations cause greater transmissibility or vaccine… […]
  • November 2021 Issue: The Big 100 – Medtech’s 100 Largest Players
      Browse the online version of the Big 100 An even larger medtech supply chain shock looms beyond the pandemic European approval ‘a big deal’ as Medtronic moves forward with Hugo surgical robot How medtech fared in the first waves of the pandemic People move the medtech industry forward The term “supply chain” brings to… […]
  • Could winged microchips monitor for airborne disease?
    Northwestern University engineers have created what they claim are the smallest-ever human-made flying structures — winged microchips that could monitor the air for disease and pollution. Engineering professor John Rogers and his team at Northwestern drew on inspiration from nature to create the microchips, which are the size of a grain of sand. The chips… […]
  • Smith+Nephew expands reach of its Cori handheld robotic system
    A year after Smith+Nephew (NYSE:SNN) launched its Cori handheld robotic system in the U.S.,  the ortho surgery system has launched globally. The British medtech giant has expanded Cori’s reach to Europe, Australia and New Zealand, India, and Canada (just announced today). The company yesterday said the system was now available for use in the U.K.’s National Health… […]
  • Elizabeth Holmes reportedly expresses remorse in criminal fraud trial
    Elizabeth Holmes reportedly revealed some regret over her handling of business as the ex-Theranos CEO took the stand again in a criminal fraud trial. Taking the stand yesterday for the third day of testimony in federal court in San Jose, California, Holmes was said to have shown remorse while still shifting some of the blame… […]
  • Supply chain, manufacturing issues slow Medtronic’s Hugo launch, ramp-up expected next fiscal year
    Medtronic (NYSE:MDT) Chair & CEO Geoff Martha confirmed that the launch of the Hugo surgical robot platform is off-schedule. Hugo received CE mark approval last month. The company is gearing up to conduct its FDA investigational device exemption (IDE) clinical trials in the U.S., with more on its stateside efforts still to come, Medtronic’s surgical robotics… […]

Leave a Reply